Home › Companies › BIOCRYST PHARMACEUTICALS INC. › 2024-2025

BIOCRYST PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings. Page generated 02 October 2026.

9Reported items
263Asset managers
1,302Fund votes
2025-06-12Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore BIOCRYST PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

How asset managers voted at the BIOCRYST PHARMACEUTICALS INC. 2024-2025 meeting

Each item below shows how the 263 asset managers that disclosed a BIOCRYST PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of BIOCRYST PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To hold a non-binding, advisory vote regarding executive compensation.

SECTION 14A SAY-ON-PAY VOTES

Combines 6 wordings of this item as funds reported it.

97% fund support · no official result

FOR 95%

The 252 asset managers below cast 97% of the shares they voted on this item FOR (137,010,743 for, 4,224,159 against).

FOR: 137,010,743 (95.4%)AGAINST: 4,224,159 (2.9%)ABSTAIN: 50,417 (0.0%)SPLIT: 2,338,592 (1.6%)NOT VOTED: 1,498 (0.0%)

Largest asset managers voting on “To hold a non-binding, advisory vote regarding executive compensation.” at BIOCRYST PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	22,114,478	0	For
BlackRock	20,676,538	0	For
State Street	10,542,511	0	For
Avoro Capital Advisors LLC	7,568,494	0	For
Fidelity	6,100,200	0	For
DEERFIELD MANAGEMENT COMPANY, L.P.	5,634,066	0	For
GEODE CAPITAL MANAGEMENT, LLC	4,996,139	0	For
Charles Schwab	3,898,687	0	For
RP Management, LLC	3,846,154	0	For
Nuveen	3,559,005	0	For
ACAP Strategic Fund	3,546,540	0	For
TIAA	3,538,660	0	For
ALKEON CAPITAL MANAGEMENT LLC	2,789,086	0	For
Fisher Asset Management, LLC	2,690,579	0	For
GW&K Investment Management, LLC	50,150	0	Split
JUPITER ASSET MANAGEMENT LTD	2,345,747	0	For
Caligan Partners LP	2,332,709	0	For
Two Sigma	2,041,712	0	For
1919 Investment Counsel, LLC	1,831,367	0	For
Invesco	0	1,797,037	Against
Northern Trust	1,763,793	0	For
RICE HALL JAMES & ASSOCIATES, LLC	1,580,426	0	For
DE Shaw	1,458,450	0	For
Columbia Threadneedle	1,456,895	0	For
Advantage Advisers Xanthus Fund, L.L.C.	1,036,408	0	For

Showing the 25 largest of 252 asset managers. See all 252 in the interactive database.

2. TO APPROVE AN AMENDED AND RESTATED STOCK INCENTIVE PLAN, INCREASING THE NUMBER OF SHARES AVAILABLE FOR ISSUANCE UNDER THE STOCK INCENTIVE PLAN.

COMPENSATION

84% fund support · no official result

FOR 84%AGAINST 16%

The 65 asset managers below cast 84% of the shares they voted on this item FOR (54,272,131 for, 10,027,610 against).

FOR: 54,272,131 (84.3%)AGAINST: 10,027,610 (15.6%)ABSTAIN: 50,417 (0.1%)

Largest asset managers voting on “TO APPROVE AN AMENDED AND RESTATED STOCK INCENTIVE PLAN, INCREASING THE NUMBER OF SHARES AVAILABLE FOR ISSUANC” at BIOCRYST PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	21,039,956	130,500	For
BlackRock	11,197,803	0	For
Fidelity	4,825,802	705,125	For
RP Management, LLC	3,846,154	0	For
ACAP Strategic Fund	3,546,540	0	For
TIAA	0	3,538,660	Against
State Street	3,240,118	4,020	For
Charles Schwab	1,949,072	0	For
Columbia Threadneedle	1,456,895	0	For
Advantage Advisers Xanthus Fund, L.L.C.	1,036,408	0	For
Invesco	0	839,792	Against
First Trust	0	650,165	Against
Equitable	328,652	273,370	For
AMG FUNDS	0	529,317	Against
John Hancock	0	464,407	Against
Voya	0	382,458	Against
HUSSMAN INVESTMENT TRUST	0	357,000	Against
Exchange Place Advisors Trust	356,586	0	For
QUANTITATIVE MASTER SERIES LLC	353,540	0	For
Segall Bryant & Hamill Trust	0	309,522	Against
Lincoln Financial	152,503	133,945	For
CLEARWATER INVESTMENT TRUST	87,221	179,165	Against
Goldman Sachs	0	250,799	Against
Federated Hermes	182,425	0	For
ALPS ETF Trust	0	152,985	Against

Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.

3. TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS FOR 2025.

AUDIT-RELATED

99.9% fund support · no official result

FOR 99.8%

The 65 asset managers below cast 99.9% of the shares they voted on this item FOR (64,280,648 for, 19,093 against).

FOR: 64,280,648 (99.9%)AGAINST: 19,093 (0.0%)ABSTAIN: 50,417 (0.1%)

Largest asset managers voting on “TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS FOR 20” at BIOCRYST PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	21,168,710	1,746	For
BlackRock	11,197,803	0	For
Fidelity	5,530,927	0	For
RP Management, LLC	3,846,154	0	For
ACAP Strategic Fund	3,546,540	0	For
TIAA	3,538,660	0	For
State Street	3,243,980	158	For
Charles Schwab	1,949,072	0	For
Columbia Threadneedle	1,456,895	0	For
Advantage Advisers Xanthus Fund, L.L.C.	1,036,408	0	For
Invesco	839,792	0	For
First Trust	650,165	0	For
Equitable	602,022	0	For
AMG FUNDS	529,317	0	For
John Hancock	464,407	0	For
Voya	382,458	0	For
HUSSMAN INVESTMENT TRUST	357,000	0	For
Exchange Place Advisors Trust	356,586	0	For
QUANTITATIVE MASTER SERIES LLC	353,540	0	For
Segall Bryant & Hamill Trust	309,522	0	For
Lincoln Financial	286,448	0	For
CLEARWATER INVESTMENT TRUST	266,386	0	For
Goldman Sachs	250,799	0	For
Federated Hermes	182,425	0	For
ALPS ETF Trust	152,985	0	For

Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.

4. Election of Directors (each to serve until the 2028 Annual Meeting of Stockholders): Alan Levin

DIRECTOR ELECTIONS

Combines 6 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99.4%

The 64 asset managers below cast 100% of the shares they voted on this item FOR (59,802,359 for, 0 against).

FOR: 59,802,359 (99.4%)ABSTAIN: 344,719 (0.6%)

Largest asset managers voting on “Election of Directors (each to serve until the 2028 Annual Meeting of Stockholders): Alan Levin” at BIOCRYST PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	21,170,456	0	For
BlackRock	11,197,803	0	For
Fidelity	5,530,927	0	For
ACAP Strategic Fund	3,546,540	0	For
TIAA	3,538,660	0	For
State Street	3,244,138	0	For
Charles Schwab	1,949,072	0	For
Columbia Threadneedle	1,456,895	0	For
Advantage Advisers Xanthus Fund, L.L.C.	1,036,408	0	For
Invesco	839,792	0	For
First Trust	650,165	0	For
Equitable	328,652	273,370	For
AMG FUNDS	529,317	0	For
John Hancock	464,407	0	For
Voya	382,458	0	For
Exchange Place Advisors Trust	356,586	0	For
QUANTITATIVE MASTER SERIES LLC	353,540	0	For
Segall Bryant & Hamill Trust	309,522	0	For
Lincoln Financial	286,448	0	For
CLEARWATER INVESTMENT TRUST	266,386	0	For
Goldman Sachs	250,799	0	For
Federated Hermes	182,425	0	For
ALPS ETF Trust	152,985	0	For
American Century	137,097	0	For
Direxion Shares ETF Trust	134,105	0	For

Showing the 25 largest of 64 asset managers. See all 64 in the interactive database.

5. Election of Directors (each to serve until the 2028 Annual Meeting of Stockholders): Steven Galson, M.D., MPH

DIRECTOR ELECTIONS

Combines 4 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99.4%

The 55 asset managers below cast 100% of the shares they voted on this item FOR (57,532,756 for, 0 against).

FOR: 57,532,756 (99.5%)ABSTAIN: 294,302 (0.5%)

Largest asset managers voting on “Election of Directors (each to serve until the 2028 Annual Meeting of Stockholders): Steven Galson, M.D., MPH” at BIOCRYST PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	21,168,643	0	For
BlackRock	11,197,803	0	For
Fidelity	5,530,927	0	For
ACAP Strategic Fund	3,546,540	0	For
TIAA	3,538,660	0	For
State Street	3,244,138	0	For
Columbia Threadneedle	1,456,895	0	For
Advantage Advisers Xanthus Fund, L.L.C.	1,036,408	0	For
Invesco	839,792	0	For
First Trust	650,165	0	For
Equitable	328,652	273,370	For
AMG FUNDS	529,317	0	For
John Hancock	464,407	0	For
Voya	382,458	0	For
HUSSMAN INVESTMENT TRUST	357,000	0	For
Exchange Place Advisors Trust	356,586	0	For
QUANTITATIVE MASTER SERIES LLC	353,540	0	For
Segall Bryant & Hamill Trust	309,522	0	For
Lincoln Financial	286,448	0	For
Goldman Sachs	250,799	0	For
CLEARWATER INVESTMENT TRUST	179,165	0	For
ALPS ETF Trust	152,985	0	For
American Century	137,097	0	For
Direxion Shares ETF Trust	134,105	0	For
AIG/SunAmerica	106,735	0	For

Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.

6. Elect Steven K. Galson

DIRECTOR ELECTIONS

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 98%

The 14 asset managers below cast 100% of the shares they voted on this item FOR (2,626,603 for, 0 against).

FOR: 2,626,603 (98.1%)ABSTAIN: 50,417 (1.9%)

Largest asset managers voting on “Elect Steven K. Galson” at BIOCRYST PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Abstain	Vote
Charles Schwab	1,949,072	0	For
Federated Hermes	182,425	0	For
Global X	121,242	0	For
Prudential/PGIM	112,600	0	For
CLEARWATER INVESTMENT TRUST	87,221	0	For
SEI	68,836	0	For
TARGET PORTFOLIO TRUST	54,000	0	For
Brighthouse	0	50,417	Abstain
New York Life	41,348	0	For
Nationwide	6,509	0	For
Vanguard	1,813	0	For
NEW COVENANT FUNDS	1,030	0	For
Principal	433	0	For
UNIFIED SERIES TRUST	74	0	For

7. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 100%

The 6 asset managers below cast 100% of the shares they voted on this item FOR (2,677,282 for, 0 against).

FOR: 2,677,282 (100.0%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at BIOCRYST PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Vote
Eversept Partners, LP	2,101,952	For
ALGERT GLOBAL LLC	405,306	For
JPMorgan	169,007	For
Coyle Financial Counsel LLC	834	For
Colony Family Offices, LLC	109	For
UNIFIED SERIES TRUST	74	For

8. 14A Executive Compensation

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 25%NOT VOTED 75%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (500 for, 0 against).

FOR: 500 (25.0%)NOT VOTED: 1,500 (75.0%)

Largest asset managers voting on “14A Executive Compensation” at BIOCRYST PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
LEAVELL INVESTMENT MANAGEMENT, INC.	0	0	0	0	Not Voted
Focus Partners Wealth	500	0	0	0	For

9. Amend Omnibus Stock Plan

SECTION 14A SAY-ON-PAY VOTES

0% fund support · no official result

AGAINST 100%

The 2 asset managers below cast 0% of the shares they voted on this item FOR (0 for, 2,102,026 against).

AGAINST: 2,102,026 (100.0%)

Largest asset managers voting on “Amend Omnibus Stock Plan” at BIOCRYST PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
Eversept Partners, LP	0	2,101,952	0	0	Against
UNIFIED SERIES TRUST	0	74	0	0	Against

Largest BIOCRYST PHARMACEUTICALS INC. shareholders voting in 2024-2025

Ranked by the number of BIOCRYST PHARMACEUTICALS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 209,208,000 shares outstanding at the time of that meeting.

Top BIOCRYST PHARMACEUTICALS INC. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	Vanguard	10.57%
2	BlackRock	9.88%
3	State Street	5.04%
4	Avoro Capital Advisors LLC	3.62%
5	Fidelity	2.92%
6	DEERFIELD MANAGEMENT COMPANY, L.P.	2.69%
7	GEODE CAPITAL MANAGEMENT, LLC	2.39%
8	Charles Schwab	1.86%
9	RP Management, LLC	1.84%
10	Nuveen	1.70%

Reported BIOCRYST PHARMACEUTICALS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

BIOCRYST PHARMACEUTICALS INC. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
Vanguard Group	22.12%	13F
BlackRock	17.05%	13F
JPMorgan Chase	9.44%	13F
T. Rowe Price	9.18%	13F
FMR (Fidelity)	8.59%	13F
State Street	7.78%	13F
RA Capital Management, L.P.	7.31%	13G
Deerfield Mgmt, L.P.	6.85%	13G
Avoro Capital Advisors LLC	6.24%	DEF14A
Franklin Templeton	6.08%	13F

Percentages above are of 209,208,000 shares outstanding, as reported by BIOCRYST PHARMACEUTICALS INC. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from BIOCRYST PHARMACEUTICALS INC.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At BIOCRYST PHARMACEUTICALS INC.'s shareholder meeting held 2025-06-12, in the 2024-2025 proxy season, 263 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,302 separate fund positions. Their filings are grouped here into 9 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. No official Form 8-K vote tally has been matched to this meeting, so this page states no certified outcome for its most widely held ballot item. On that item — To hold a non-binding, advisory vote regarding executive compensation. — the reporting funds cast 97% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

BIOCRYST PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.